Changwei W. Wu1,2, Zi-Xuan Chang3, I-Ling Chung4, Chien-Yuan Lin5, Ching-Po Lin6, Chi-Bin Yeh7, and Hong-Wen Kao4
1Graduate Institute of Humanities in Medicine, Taipei Medical University, Taipei, Taiwan, 2Brain and Consciousness Research Center, Taipei Medical University, Taipei, Taiwan, 3Department of Biomedical Sciences and Engineering, National Central University, Taoyuan, Taiwan, 4Department of Radiology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, 5GE Healthcare, Taipei, Taiwan, 6Institute of Neuroscience, National Yang-Ming University, Taipei, Taiwan, 7Department of Psychiatry, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
Synopsis
We revisited the sertraline treatment effect on
RSFC in drug-naïve MDD patients and evaluated the association between RSFC,
ALFF and baseline CBF level. Twenty-four unmedicated MDD subjects were recruited and treated with sertraline for 6 weeks. Results showed negative correlation between HAM-D scores and striatum-MPFC RSFC. However, the therapeutic effect on RSFC was irrelevant to
the CBF or ALFF levels, implying better temporal synchronizations from the neural basis.
INTRODUCTION
Sertraline, an effective
antidepressant for major depressive disorder (MDD), is shown to enhance
amygdala and striatum connectivity in MDD patients1,2. However, the
sertraline effect on brain connectivity remains elusive, which could be either
from perfusion or from neuronal connections. To this point, we revisited
sertraline treatment effect and acquired both resting-state fMRI (RS-fMRI) and
arterial spin labeling (ASL) in MDD patients for clarifying its underlying
mechanism.METHODS
We recruited 24 unmedicated MDD subjects (age: 42.3±11.3, 6 males) and
33 healthy control subjects (HC, age: 41.5±10.3, 10 males) and collected their Hamilton
depression rating scale (HAM-D). FMRI scans were carried out on a 3T MR scanner (GE MR750) using 8-channel coil (RS-fMRI settings: GE-EPI with matrix size=64x64, 200 measurements, TR/TE=2500/30 ms, flip angle of 90; ASL in the same settings with TI=2025 ms). After the baseline scan
(Pre), the patient started sertraline treatment and then received the second
scan after six weeks (Post). The fMRI data underwent the standard preprocessing
using SPM8, whereas functional connectivity and amplitude of low-frequency
fluctuations (ALFF) were performed using REST for striatum, amygdala and
default-mode network (DMN). Group comparisons were conducted by paired t-test
(Post vs. Pre) or two-sample t-test (HC vs. Pre) on Z-map, ALFF and CBF
(uncorrected p<0.001). RESULTS
After the 6-week sertraline treatment, the drug-naïve MDD patients
expressed significant reduction on HAM-D scale (p<0.05). Compared with HC,
the MDD patients showed declined RSFC between the striatum and the medial prefrontal
cortex (MPFC, BA 10). After the treatment, the RSFC of striatum-MPFC was
enhanced and returned back to the normal level, and the striatum connectivity
to MPFC correlated with HAM-D score in MDD patients. However, the therapeutic
effect was not observed in the perfusion levels, neither was ALFF. At last, we
did not observe therapeutic effects on amygdala and DMN. DISCUSSION
Sertraline treatment in MDD patients showed network specificity on the
resting-state functional connectivity, but the therapeutic effect is not
associated with changes of CBF and ALFF. In other words, the
therapeutic effect on RSFC was not contributed from the alterations of baseline
blood flow level or from the fluctuation strength. Since sertraline serves as
the serotonin reuptake inhibitor and increases serotonin levels, the unchanged
fluctuation and perfusion levels suggested that enhanced striatum-MPFC RSFC was resulted
from a better temporal synchronization without time delays. CONCLUSION
We revisited the sertraline treatment effect on
RSFC in drug-naïve MDD patients and evaluated the association between RSFC,
ALFF and baseline CBF level. The therapeutic effect on RSFC was irrelevant to
the CBF or ALFF levels, implying better neural synchronizations between target
regions. Acknowledgements
No acknowledgement found.References
1. Anand A, Li Y, Wang Y, et al. Antidepressant Effect on Connectivity of the Mood-Regulating Circuit: An fMRI
Study. Neuropsychopharmacology 2005;30(7):1334-44.
2. Anand A, Li Y, Wang Y, et al. Reciprocal Effects of Antidepressant Treatment on Activity and Connectivity of
the Mood Regulating Circuit: An fMRI Study. J Neuropsychiatry Clin Neurosci,
2007;19(3):274-82